• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of sexual medicine >Impact of Medical Treatments for Male Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia on Ejaculatory Function: A Systematic Review and Meta-Analysis
【24h】

Impact of Medical Treatments for Male Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia on Ejaculatory Function: A Systematic Review and Meta-Analysis

机译：良性前列腺增生引起的男性下尿路症状的药物治疗对射精功能的影响：系统评价和荟萃分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction Several drugs, currently used to treat lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH), can be associated with bothersome sexual side effects, including ejaculatory dysfunction (EjD). Aim To provide a systematic review and meta-analysis of the available randomized clinical trials (RCTs) reporting the impact of medical treatments for LUTS due to BPH on ejaculatory function. Main Outcome Measure EjD related to medical treatments for LUTS. Methods A systematic literature search was performed using PubMed, Scopus and Cochrane databases. EjD was identified using both free text (ejaculat*, retrograde ejaculation, anejaculation, ejaculatory dysfunction) and Mesh (Ejaculation) searches. Results Of 101 retrieved articles, 23 were included in the present meta-analysis. EjD was significantly more common with alpha-blockers (ABs) than with placebo (OR:5.88; P<0.0001), in particular, considering Tamsulosin (OR:8.58; P=0.006) or Silodosin (OR:32.5; P<0.0001), with Tamsulosin associated with significantly lower risk of EjD than Silodosin (OR:0.09; P<0.00001). Conversely, Doxazosin and Terazosin were associated with a risk similar to placebo. Meta-regression showed that EjD was associated with IPSS and with Qmax both before and after treatment with ABs, while multivariate analysis demonstrated that EjD was independently associated with the improvement of IPSS (adj.r:0.2012; P<0.0001) and Qmax (adj.r:0.522; P<0.0001). EjD was significantly more common with 5ARIs as compared with placebo (OR:2.73; P<0.0001). Both Finasteride (OR 2.70; P<0.0001) and Dutasteride (OR 2.81; P=0.0002) were associated with significantly higher risk of EjD than placebo. EjD was significantly more common with combination therapy as compared with ABs alone (OR:3.75; P<0.0001),or with 5ARIs alone (OR:2.76; P=0.02). Conclusions ABs and 5ARI were both associated with significantly higher risk of EjD than placebo. More the AB is effective over time, greater is the incidence of EjD. Finasteride has the same risk of Dutasteride to cause EjD. Combination therapy with ABs and 5ARIs resulted in a 3-fold increased risk of EjD as compared with ABs or 5ARIs alone. These data can be relevant both for drug selection and patients counseling. Gacci M, Ficarra V, Sebastianelli A, Corona G, Serni S, Shariat SF, Maggi M, Zattoni F, Carini M, and Novara G. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: A systematic review and meta-analysis. J Sex Med 2014;11:1554-1566.
机译：引言目前，由于良性前列腺增生（BPH），目前用于治疗下尿路症状（LUTS）的几种药物可能与包括射精功能障碍（EjD）在内的烦扰性副作用相关。目的对现有的随机临床试验（RCT）进行系统的回顾和荟萃分析，报告由于BPH引起的LUTS药物治疗对射精功能的影响。与LUTS的药物治疗相关的主要结果指标EjD。方法使用PubMed，Scopus和Cochrane数据库进行系统的文献检索。使用自由文本（射精*，逆行射精，射精，射精功能障碍）和网状（射精）搜索来识别EjD。结果检索的101篇文章中，有23篇纳入荟萃分析。 EjD在α受体阻滞剂（AB）中比在安慰剂中更为常见（OR：5.88; P <0.0001），特别是考虑坦索罗辛（OR：8.58; P = 0.006）或西洛多辛（OR：32.5; P <0.0001） ，坦索罗辛的EjD风险明显低于西洛多辛（OR：0.09; P <0.00001）。相反，多沙唑嗪和特拉唑嗪的风险与安慰剂相似。荟萃回归表明，EjD与ABs治疗前后IPSS和Qmax相关，而多变量分析表明EjD与IPSS（adj.r：0.2012; P <0.0001）和Qmax（adj .r：0.522; P <0.0001）。与安慰剂相比，5ARIs的EjD更为常见（OR：2.73; P <0.0001）。 Finasteride（OR 2.70; P <0.0001）和Dutasteride（OR 2.81; P = 0.0002）的EjD风险均显着高于安慰剂。与单独使用ABs（OR：3.75; P <0.0001）或单独使用5ARIs（OR：2.76; P = 0.02）相比，联合治疗的EjD更为常见。结论与安慰剂相比，ABs和5ARI均与EjD风险显着相关。随着时间的流逝，AB越有效，EjD的发生率越大。非那雄胺与Dutasteride引起EjD的风险相同。与单独使用ABs或5ARIs相比，ABs和5ARIs的联合治疗导致EjD风险增加3倍。这些数据可能与药物选择和患者咨询有关。 Gacci M，Ficarra V，Sebastianelli A，Corona G，Serni S，Shariat SF，Maggi M，Zattoni F，Carini M和Novara G.由于良性前列腺增生引起的男性下尿路症状的药物治疗对射精功能的影响：系统的审查和荟萃分析。 J Sex Med 2014; 11：1554-1566。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号